Activity of Bortezomib in advanced non - Small-cell lung cancer

Clinical Lung Cancer

Volumn 6, Issue 3, 2004, Pages 141-142

  Reddy, G Kesava ^a   Belani, Chandra P ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CYCLINE; DOCETAXEL; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CELL DEATH; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

EID: 10244249100     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70211-X     Document Type: Article

References (7)

1. Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95:176-180.
2. Bunn PA Jr. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res 2004; 10:4263s-4265s.
3. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-1154.
4. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-2511.
5. Stevenson J, Nho CW, Schick J, et al. Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:202 (Abstract #810).
6. Fanucchi MP, Belt RJ, Fossella TV, et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 2004; 23:640 (Abstract #7107).
7. Davies AM, Lara PN, Lau DH, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. Proc Am Soc Clin Oncol 2004; 23:639 (Abstract #7106).